Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
NCT ID: NCT05364905
Last Updated: 2023-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2022-05-09
2022-11-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sub-type Specific Genomic Mutations in sBOTs
NCT03883542
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT05691010
Expression Analysis of the COPB 2 and Bcl-2 in Early Stages of Endometrial Carcinoma
NCT05951426
GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer
NCT01397877
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
NCT04205630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019
Chemotherapy
Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Cohort 2
Patients in second line treatment (after one prior systemic chemotherapy) in 2019
Chemotherapy
Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemotherapy
Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. Patients with interval surgery after primary CT may be eligible.
3. Index date should represent at least the first\* or second line\*\* chemotherapy systemic treatment and occur between, 1, January 2019 and 31, December 2019.
4. do not express refusal to her personal data processing or did not express her refusal for deceased patients.
Exclusion Criteria
2. Patients with active malignancy other than EC cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion.
3. Patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased).
4. Patient did not receive chemotherapy systemic treatment.
5. Patient undergo treatment by pembrolizumab or another immunotherapy in first line (cohort 1) or second line (cohort 2) during the eligibity (inclusion) period.
18 Years
99 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Victor Dupouy
Argenteuil, , France
Sainte-Catherine Institut du Cancer Avignon-Provence
Avignon, , France
CHRU Besançon - Hôpital Jean Minjoz
Besançon, , France
Guillaume BABIN
Bordeaux, , France
Hôpital Morvan CHRU de Brest
Brest, , France
Centre d'Oncologie et de Radiothérapie 37
Chambray-lès-Tours, , France
Hôpital Louis Mourier
Colombes, , France
Centre Hospitalier Intercommunal de Créteil
Créteil, , France
CHU de Dijon
Dijon, , France
Centre Georges François Leclerc
Dijon, , France
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, , France
Centre Oscar Lambret
Lille, , France
Centre Léon Bérard
Lyon, , France
ICL - Centre Alexis Vautrin
Nancy, , France
ORACLE - Centre d'Oncologie de Gentilly
Nancy, , France
Hôpital Privé du Confluent
Nantes, , France
Centre Antoine Lacassagne
Nice, , France
Centre ONCOGARD - Institut de cancérologie du Gard
Nîmes, , France
CHR Orléans
Orléans, , France
Institut Curie
Paris, , France
Hôpital Cochin
Paris, , France
Hôpital Européen Georges Pompidou
Paris, , France
Groupe Hospitalier Diaconesses - Croix Saint-Simon
Paris, , France
Centre CARIO - HPCA
Plérin, , France
CHU de Poitiers - Hôpital de la Milétrie
Poitiers, , France
Centre Eugène Marquis
Rennes, , France
ICO - Centre René Gauducheau
Saint-Herblain, , France
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, , France
CHU Tours - Hôpital Bretonneau
Tours, , France
Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GINECO-EN106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.